Dr. Denise Galloway gets inducted into Washington Life Science Hall of Fame. This hall of fame honors “innovative leaders and industry pioneers in Washington state who have made a significant contribution to the life sciences.”
Read more >
Integrating fundamental, applied and translational scientists to improve the diagnosis, treatment and prevention of cancer and other diseases.
Human Biology researchers come together to form a multidisciplinary team that is influenced by individual advances. Their diverse expertise include molecular and cell biology, genomics, genetics, virology, infectious disease, computational biology, pathology and clinical research. Grounded in high-quality basic science, the research performed in Human Biology blends fundamental, applied, and translational research performed in model organisms and in vitro systems.
Highlights
- Highlight 1
- Highlight 2
Glioblastoma is a deadly cancer that is largely unresponsive to treatment. There are a variety of immune cells that, in some cases, have been shown to promote tumor growth. Targeting these cells could serve as a potential therapy, however these immune and tumor cells are poorly understood. Authors from the Holland lab and colleagues from the University of Washington and Emory University examine one molecule that is thought to play a role in these interactions.
Read more >- Highlight 3
Dr. Sita Kugel receives a one-year $100,000 grant from the Neuroendocrine Tumor Research Foundation to study how a gene involved in modifying DNA may contribute to suppressing the development of pancreatic neuroendocrine tumors.
Read more >- Highlight 4
The vast majority of prostate carcinomas are highly dependent on androgen receptor (AR) signaling. Because of this, the first line therapies for prostate cancers are AR pathway inhibitors. The widespread use of AR-repressing chemotherapies has impacted AR status of prostate metastases. In a recent paper, Dr. Pete Nelson and first author Dr. Eric Bluemn, as well as colleagues from centers around the country, show that AR-directed therapies are resulting the emergence of prostate metastases devoid of AR signaling and discover an effective pathway to target in these AR-null cancers.
Read more >- Highlight 5
Together Fred Hutch, UW Medicine and SCCA are working to develop the most precise treatment options for patients with solid tumor cancers. The primary goal is to translate laboratory sciences into the most precise treatment options for patients with solid tumor cancers.
Learn more about STTR >- Highlight 6
Dr. Nina Salama receives one of the PAM IRC Innovation Awards to examine how the stomach pathogen h-pylori may influence the development of gastric cancer subtypes and the immune response to gastric cancer.
Read more >- Highlight 7
Dr. Alice Berger receives the Lori Monroe Scholarship for Lunch Cancer Research. She will use the scholarship to further her scientific focus on the genetics of lunch cancer in women who have never smoked.
Read more >- Highlight 8
A virus can only enter a host cell if specific receptors are present on the host cell surface. In order for HIV-1 to bind to a host cell, glycoprotein CD4 must be present. John Nahabedian and his colleagues in the Overbaugh lab are working to better understand the functions of these receptors.
Read more >- Highlight 9
A new study, led by Drs. Stephen Tapscott and Amy Campbell, has revealed more players in the pathway of facioscapulohumeral muscular dystrophy, or FSHD, the most common form of muscular dystrophy. Their study, published in eLife, is the first to systematically identify proteins involved in repressing the FSHD-triggering gene, DUX4.
Read more >- Highlight 10
Dr. Chris Kemp and collaborators receive two new National Cancer Institute grants, totaling more than $7 million, to further their new drug trial against head and neck cancer.
Read more >
